Johnson & Johnson on Tuesday reported adjusted earnings and revenue that topped Wall Street's expectations, and lifted its full-year guidance as sales in the company's pharmaceutical and medical devices businesses surged.
Upon that split, J&J lowered its full-year sales and profit guidance.
J&J also expects adjusted earnings per share of $10.07 to $10.13, up from a previous forecast of $10.00 to $10.10.
The pharmaceutical giant reported net income of $4.31 billion, or $1.69 per share.
That was flat compared with net income of $4.31 billion, or $1.62 per share, for the same period a year ago.
Persons:
Johnson, J, Joseph Wolk
Organizations:
LSEG